# Neurology (headache medicine) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Friedrich Nietzsche (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI019-SYN
- Date: 2026-07-21
- Fictional facility: St. Posthumous Health Center
- Fictional author: Ingeborg Achterberg-Sato, MD
- Calendar frame: modern shifted

- Requested by: Konrad Ellison-Mbatha, MD

## Reason for consultation

Headache on about 20 days a month with nausea, vomiting and light sensitivity, mostly right-sided, since childhood and more frequent over the past year, with a butalbital combination taken on most headache days, in a 36-year-old writer with high myopia. Please confirm the diagnosis and advise on withdrawal of the tablets and on preventive treatment. **S**

## History

Mr. Nietzsche, a 36-year-old writer and former professor, is seen at the request of Dr. Ellison-Mbatha with a 14-day diary, an MRI done this morning and a comprehensive eye examination done today. Headaches began in childhood and have grown more frequent and severe in adult life; for at least eight months he has had headache on about 20 days a month. In the diary, headache came on 10 of 14 days: on 7 it was moderate or severe, throbbing, mostly over the right forehead and eye, worse with walking uphill and reading, with light and noise sensitivity and nausea, and vomiting on 3, lasting six hours to two days; on 3 it was a milder pressure. He has never had an aura. He took the butalbital combination on 9 days and ibuprofen on 2. He has no history of seizures, drinks little and takes no other sedatives. He sleeps four to five hours and has occasional constipation. **S**

## Examination

| System | Finding |
|---|---|
| General | Comfortable today; blood pressure 116/74, pulse 66 |
| Eyes | Right pupil about 1 mm larger than the left in light and dark, both reacting briskly, no afferent defect, no ptosis; eye movements full; no papilledema |
| Neurological | Cranial nerves otherwise normal; strength, sensation, reflexes, coordination and gait normal |
| Head and neck | Tenderness of the right occipital and neck muscles; temporal arteries normal |

BP 116/74 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 98% on room air; weight 66.2 kg; BMI 21.9 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Ellison-Mbatha's intake note and the diary. MRI of the brain and orbits without and with contrast: normal brain, pituitary and optic nerves, no mass or white matter lesions; elongated globes with a right posterior staphyloma. Treponemal antibody 0.12 (nonreactive) and RPR nonreactive. Eye examination today: best corrected vision 20/100 right and 20/20 left, refraction about -13.50 and -6.25, intraocular pressure 15 and 14 mmHg, pathologic myopia of the right eye with macular atrophy and no neovascularization, no retinal breaks. MIDAS 74 and HIT-6 68 at intake; PHQ-9 7, GAD-7 6. Blood pressure 116/74 and pulse 66 today. Treponemal antibody (immunoassay index): 0.12; Intraocular pressure, right eye: 15 mmHg; Intraocular pressure, left eye: 14 mmHg. All results are synthetic.

## Assessment

1. **Chronic migraine without aura** (G43.709). ICHD-3 criteria for chronic migraine are met: headache on 15 or more days a month for more than three months, with features of migraine without aura (throbbing, moderate to severe, worse with activity, with nausea, vomiting and light and noise sensitivity) on at least 8 days a month. The milder pressure days are part of the same disorder. Cluster headache and hemicrania continua do not fit: there are no tearing, redness or other autonomic signs, and the pain is not continuous. **S**
2. **Medication overuse headache** (G44.40). Present: a combination analgesic on 10 or more days a month for more than three months in a person with 15 or more headache days a month. Butalbital is a barbiturate and should be tapered rather than stopped at once; ibuprofen can be stopped now. **S**
3. **Secondary causes** (G43.709). The strongly right-sided pattern and the rising frequency justified imaging, and the MRI with contrast shows no structural lesion, including none behind the right eye. Nonreactive treponemal and nontreponemal tests exclude syphilis as a cause of the headaches or the pupils, and no lumbar puncture is needed. The unequal pupils, both briskly reactive and present since early childhood, are long-standing and benign, and the poor right eye is explained by myopic macular atrophy. His father's illness cannot be diagnosed from the record; nothing in his own history, examination or MRI suggests an inherited neurological disease, and no genetic testing is indicated. **S**
4. **Preventive treatment** (G43.709). Prevention is indicated for chronic migraine with severe disability. A CGRP monoclonal antibody is a first-line option under the 2024 American Headache Society position statement and the European Headache Federation guideline, which also supports starting it with withdrawal in medication overuse headache. Galcanezumab suits him: monthly self-injection travels well between his summer and winter homes, and it causes constipation less often than erenumab. Topiramate is a poor fit because it can slow word-finding and concentration and, rarely, cause acute myopia with angle-closure glaucoma. OnabotulinumtoxinA is effective in chronic migraine but needs injections every 12 weeks at a center; it is the next option if the antibody is not enough. **S**
5. **Pathologic myopia and headache** (H44.2E1). Eye strain from uncorrected anisometropia can add to headache on reading days; contact lenses should make reading more comfortable. Flashes and floaters in a highly myopic eye need same-day examination and should not be mistaken for aura. **S**

## Recommendations

1. Stop ibuprofen now. Replace as-needed butalbital combination tablets with a scheduled taper: one tablet twice a day for 7 days, once a day for 7 days, every other day for 7 days, then stop. Expect worse headache for one to two weeks; seek same-day care for tremor, sweating, agitation, confusion or a seizure. A nurse phone check at the end of the first week.
2. Galcanezumab 240 mg subcutaneously today as a loading dose, then 120 mg every four weeks; judge the effect at about three months, seeking at least half as many migraine days and fewer than 15 headache days a month.
3. Acute treatment during and after the taper: naproxen 500 mg with metoclopramide 10 mg early in an attack, no more than two days a week; add sumatriptan 100 mg once the taper is complete, no more than eight triptan days a month; no butalbital, opioids or caffeine combination products.
4. OnabotulinumtoxinA if the antibody fails or the response fades.
5. Count every acute-medicine day in the diary; review at four weeks and at eight weeks with the MIDAS, HIT-6, PHQ-9 and GAD-7.
6. Contact lenses for both eyes, an Amsler grid for the right eye, and same-day eye care for new flashes, floaters or a shadow.
7. CBT-I for insomnia, with no sedative sleeping tablets; regular meals, a fixed rising time, and his daily walks.
8. Before he leaves for the winter, a three-month review and a written plan, with his diary and injection supplies, for care near his winter home.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Ellison-Mbatha, who saw him the same day. The diagnosis, the MRI and serology results, and the reasons for each step were explained to Mr. Nietzsche, who asked whether his headaches meant an illness like his father's and was reassured by the normal results. He chose galcanezumab after weighing it against topiramate and onabotulinumtoxinA, and the first dose was given in clinic. **S**

## Follow-up

Dr. Ellison-Mbatha continues care at four and eight weeks and at three months; headache medicine will see him again if prevention fails, the pattern changes, or onabotulinumtoxinA is needed. **S**

## Guideline basis

- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018), International Headache Society (Cephalalgia 2018;38(1):1-211)
- The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021), American Headache Society (Headache 2021;61(7):1021-1039)
- Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update (2024), American Headache Society (Headache 2024;64(4):333-341)
- European Academy of Neurology guideline on the management of medication-overuse headache (2020), European Academy of Neurology (European Journal of Neurology 2020;27(7):1102-1116)
- European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update (2022), European Headache Federation (Journal of Headache and Pain 2022;23(1):67)
- Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation (2018), European Headache Federation (Journal of Headache and Pain 2018;19(1):91)
- Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question (2013), American Headache Society (Headache 2013;53(10):1651-1659)
- Sexually Transmitted Infections Treatment Guidelines, 2021 (2021), Centers for Disease Control and Prevention (MMWR Recommendations and Reports 2021;70(4):1-187)
- Refractive Errors Preferred Practice Pattern (2023), American Academy of Ophthalmology (Ophthalmology 2023;130(3):P1-P60)
